Improving human kidney function in renovascular disease with mesenchymal stem cell therapy

Kisha N Sivanathan; P Toby Coates

doi:10.1016/j.kint.2019.12.020

Improving human kidney function in renovascular disease with mesenchymal stem cell therapy

Kidney Int. 2020 Apr;97(4):655-656. doi: 10.1016/j.kint.2019.12.020.

Authors

Kisha N Sivanathan¹, P Toby Coates²

Affiliations

¹ Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA; School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
² School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia; Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, South Australia, Australia. Electronic address: Toby.Coates@sa.gov.au.

PMID: 32200860
DOI: 10.1016/j.kint.2019.12.020

Abstract

A dose escalation study of adipose-derived human mesenchymal stem cell (MSC) therapy was studied in 21 subjects. This dose escalation study confirmed no significant cellular toxicity, but it showed improvement in renal oxygenation and glomerular filtration rate. No significant renal toxicity from cell therapy was shown. A reduction in inflammatory markers including tumor necrosis factor-α, interferon-γ, and neutrophil gelatinase-associated lipocalin was noted in subjects receiving MSC therapy. This study provides short-term safety and renal efficacy for MSC therapy and paves the way forward for future MSC-based interventions in renovascular disease.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biomarkers
Blood Pressure
Glomerular Filtration Rate
Humans
Kidney
Mesenchymal Stem Cells*

Substances

Biomarkers